DV in Combination With Pertuzumab With or Without Toripalimab Neoadjuvant Therapy With HER2-positive Breast Cancer

This trial is testing a neoadjuvant (pre-surgery) treatment combination for HER2-positive breast cancer: an antibody-drug conjugate (DV — disitamab vedotin) combined with pertuzumab, with or without a third immunotherapy drug (toripalimab), to see if this achieves better tumor shrinkage before surgery compared to standard approaches. **You may be eligible if...** - You are 18 or older with HER2-positive invasive breast cancer - Your tumor is 2 cm or larger (clinical T2-T3) and has not spread to distant organs - You have not received any prior anti-cancer treatment for your breast cancer - Your heart function is normal (ejection fraction 55% or higher) - You are willing and able to undergo breast cancer surgery after treatment **You may NOT be eligible if...** - Your breast cancer is HER2-negative - Your tumor has spread to distant organs (stage IV) - You have received any prior treatment for breast cancer - You have significant heart disease or poor cardiac function - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.